© 2025 HSP News Service, L.L.C.
The Dutch and Belgian NELSON trial is assessing the effect of increasing interval low-dose computed tomography (CT) screening for lung cancer on lung cancer mortality. In an analysis of screening test performance among Dutch participants reported in Lancet Oncology, Horeweg and colleagues found...
Analysis of 607 small cell lung cancer (SCLC) tumors and neuroendocrine tumors identified common molecular markers among both groups that could reveal new therapeutic targets for patients with similar types of lung cancer, according to research presented at the 2014 Chicago Multidisciplinary...
Lung cancer patients with minimally invasive adenocarcinoma have similar, positive 5-year disease-free survival and overall survival rates as patients with adenocarcinoma in situ, according to research presented today at the 2014 Chicago Multidisciplinary Symposium in Thoracic Oncology (Abstract...
Biopsies were found to be the most costly tool prescribed in lung cancer diagnosis, according to research presented today at the 2014 Chicago Multidisciplinary Symposium in Thoracic Oncology (Abstract 103). The study examined the utilization rates and estimated the Medicare costs of the lung...
Patients at high-risk for developing lung cancer are more likely to receive low-dose computed tomography (CT) screening when their primary care provider is familiar with guideline recommendations for low-dose CT screening for lung cancer, according to research presented today at the 2014 Chicago...
In a study reported in the Journal of Clinical Oncology, Backhus et al found that imaging guideline recommendations for staging of locally advanced lung cancer were often not followed in a national Veterans Affairs (VA) cohort. Study Details The study involved 3,808 patients with stage IIB, IIIA, ...
The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to the anti–PD-1 therapy pembrolizumab (Keytruda) for the treatment of patients with epidermal growth factor receptor (EGFR) mutation–negative, and anaplastic lymphoma kinase (ALK)...
In a phase III ARCHER 1009 trial reported in The Lancet Oncology, Ramalingam et al found no progression-free survival benefit of the irreversible pan-HER tyrosine kinase inhibitor dacomitinib vs erlotinib among all patients with pretreated non–small cell lung cancer (NSCLC) or among those...
In the phase III NCIC CTG BR.26 Trial reported in The Lancet Oncology, Ellis et al found that treatment with the irreversible pan-HER tyrosine kinase inhibitor dacomitinib was not associated with an overall survival benefit compared with placebo in patients with pretreated advanced or...
A new study shows that patients with stage I to III non–small cell lung cancer have different metabolite profiles in their blood than those of patients who are at risk but do not have lung cancer. The study abstract was released today in an online supplement to the journal CHESTand will be...
In smokers with non–small cell lung cancer (NSCLC), the relationship between KRAS mutations and NQO1 may be of future therapeutic value, according to the study findings presented by Yilmaz et al in the International Journal of Environmental Research and Public Health. The researchers...
At least 14 million major medical conditions among U.S. adults aged 35 years and older were attributed to cigarette smoking by a study estimating the disease burden of cigarette smoking, which, according to the study’s authors, “remains immense.” Among current and former smokers,...
ASCO has endorsed the recently developed joint College of American Pathologists (CAP), International Association for the Study of Lung Cancer (IASLC), and Association of Molecular Pathologists (AMP) guideline on molecular testing for selection of patients with lung cancer for EGFR and ALK inhibitor ...
Known cancer-driving genomic aberrations in localized lung cancer appear to be so consistently present across tumors that a single biopsy of one region of the tumor is likely to identify most of them, according to a paper published by Zhang et al in Science. The study led by scientists at The...
An investigative predictive model for lung cancer demonstrated more accuracy than the more commonly used Mayo Clinic model in prescreening lung nodules prior to resection, according to the results of a study reported by Deppen et al in the Journal of Thoracic Oncology. The investigators suggested...
Although positron-emission tomography (PET) combined with 18F–fluorodeoxyglucose (FDG) is recommended for the noninvasive diagnosis of pulmonary nodules suspicious for lung cancer, in populations with endemic infectious lung disease, FDG-PET may not accurately identify malignant lesions. An...
The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to Ariad Pharmaceutical’s investigational agent AP26113 for patients with anaplastic lymphoma kinase (ALK)-positive metastatic non–small cell lung cancer (NSCLC) who are resistant to crizotinib...
The MAGRIT trial showed disappointing results for a developmental vaccine called MAGE-3 in patients with non–small cell lung cancer (NSCLC) who had undergone surgical resection. This is the largest vaccine trial conducted in lung cancer, and investigators hoped that an immunotherapy approach...
For the first time, studies show that a drug is effective in treating cancer-related cachexia. Oral anamorelin hydrochloride increased lean body mass, achieved weight gain, and improved quality of life in patients with cancer-related cachexia in two pivotal phase III studies presented at the ESMO...
The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designations to aldoxorubicin in three indications: glioblastoma multiforme, small cell lung cancer, and ovarian cancer. Aldoxorubicin combines doxorubicin with a novel single-molecule linker that binds directly and...
A new study found that the average cost to screen high-risk individuals for lung cancer with low-dose computed tomography (CT) plus the average cost of curative-intent treatment is lower than the average cost to treat advanced-stage lung cancer, which quite rarely results in a cure. The findings by ...
In the phase I portion of a phase I/II study reported in The Lancet Oncology, Gadgeel et al found that the novel ALK inhibitor alectinib showed activity against systemic disease and brain metastases in patients with non–small cell lung cancer (NSCLC) resistant to the ALK inhibitor crizotinib...
In a European phase III trial reported in The Lancet, Slotman et al found benefits of thoracic radiotherapy in patients with extensive-stage small cell lung cancer who had responded to chemotherapy and had received prophylactic cranial radiotherapy. Although thoracic radiotherapy did not...
In a systematic review and meta-analysis of individual patient data reported in The Lancet Oncology, Rossi et al found no overall survival benefit with six vs fewer than six planned cycles of first-line platinum-based treatment in patients with advanced non–small cell lung cancer (NSCLC). A...
In the SMaRT Oncology-3 study reported in The Lancet Oncology, Walker et al found that an integrated collaborative treatment program for depression (‘depression care for people with cancer’) was associated with significantly reduced severity of depression compared with usual care in...
A large, international analysis of patients with stage IV non–small cell lung cancer (NSCLC) indicates that a patient’s overall survival rate can be related to factors including the timing of when metastases develop and lymph node involvement, and that aggressive treatment for low-risk...
Patients with inoperable, early-stage lung cancer who receive stereotactic body radiation therapy have a 5-year survival rate of 40%, according to long-term results presented at the American Society for Radiation Oncology’s (ASTRO) 56th Annual Meeting (Abstract 56). Such a positive survival...
In a recent study investigating alectinib resistance in ALK-positive lung cancers, researchers identified two novel ALK mutations that are sensitive to ceritinib (Zykadia), a next-generation ALK tyrosine kinase inhibitor approved by the FDA earlier this year for advanced non–small cell lung...
Compared with mutations in EGFR, KRAS, or with patients with no known mutations, ALK rearrangements were independently associated with improved survival outcomes in patients with non–small cell lung cancer (NSCLC) who received radiotherapy for brain metastases, according to the results of a...
Findings from the National Lung Screening Trial (NLST) showed that screening high-risk individuals (smoking history of ≥ 30 pack-years) aged 55 to 74 with low-dose computed tomography (CT) vs chest radiography reduced lung cancer mortality. Following the study results, the U.S. Preventive...
In the phase III REVEL trial reported in The Lancet, Garon et al found that the addition of the antiangiogenic VEGFR-2 inhibitor ramucirumab (Cyramza) to docetaxel produced a statistically significant improvement in overall survival as second-line treatment in patients with non–small...
Epidermal growth factor receptor (EGFR) mutations found in the circulating-free tumor DNA from the plasma of advanced non–small cell lung cancer (NSCLC) patients correlates well with the EGFR mutations from patient-matched tumor tissue DNA, according to new data reported by Douillard et...
Links between a number of common respiratory diseases and an increased risk of developing lung cancer have been found in a large pooled analysis of seven studies involving more than 25,000 individuals. The findings by Denholm et al were published in the American Journal of Respiratory and Critical...
The European Thoracic Oncology Platform Lungscape ALK project is investigating the prevalence and prognostic impact of ALK-positivity in resected lung adenocarcinoma in a primarily European population. As reported in the Journal of Clinical Oncology by Blackhall and colleagues, the project has...
The Cancer Genome Atlas Research Network has recently reported its comprehensive molecular profiling of lung adenocarcinoma in Nature. Findings included a high rate of somatic mutations including alterations in tumor-suppressor genes, chromatin-modifying genes, and RNA-splicing genes and suggested...
A new analysis confirms that U.S. lung cancer rates are declining overall, but it also uncovers previously unrecognized trends related to cancer subtype, sex, race/ethnicity, and age. Published early online in Cancer, the findings provide a more accurate picture of the state of lung cancer in the...
Nearly half of adult patients with lung-only metastases from Ewing sarcoma who received whole-lung irradiation were free of pulmonary relapse at 3 years, according to the results of a retrospective study in the International Journal of Radiation Oncology • Biology • Physics. With few...
A phase Ib study has found that a combination of the EGFR-targeted agents afatinib (Gilotrif) and cetuximab (Erbitux) yielded clinical responses in patients with EGFR-mutant lung cancer that had stopped responding to the EGFR inhibitors erlotinib (Tarceva) and gefitinib (Iressa). The combination...
Early surveillance imaging (< 6 months) after stereotactic body radiation therapy for early-stage non–small cell lung cancer (NSCLC) seems to be of limited benefit, resulting in definitive intervention in only 3% of patients, according to the findings of a study in Practical Radiation...
Noninvasive quantitative computed tomography–based texture analysis can accurately differentiate the presence of a KRAS mutation from pan–wild-type non–small cell lung cancer (NSCLC), based on the results of a study in PLOS ONE. Weiss et al reported that this tumor heterogeneity...
New research raises the prospect of more effective treatments for cachexia, a profound wasting of fat and muscle occurring in about half of all cancer patients, raising their risk of death, according to scientists from Dana-Farber Cancer Institute. In a study reported in Nature, Spiegelman et al...
The phase II Southwest Oncology Group (SWOG) S0802 trial reported in the Journal of Clinical Oncology by Allen et al showed that adding ziv-aflibercept (Zaltrap) to topotecan improved 3-month progression-free survival, but increased toxicity and had no effect on overall survival, in patients...
Researchers from Dana-Farber Cancer Institute, the Broad Institute of MIT and Harvard, and other centers have identified novel mutations in a well-known cancer-causing pathway in lung adenocarcinoma, the most common subtype of lung cancer. Knowledge of these mutations could potentially identify a...
Recent retrospective, single-institution analyses have suggested that anatomic segmentectomy results in freedom from recurrence and survival rates similar to those achieved by lobectomy in lung cancer. In a large propensity-matched analysis reported in the Journal of Clinical Oncology, Landreneau...
In the phase III American College of Surgeons Oncology Group (ACOSOG) Z4032/Alliance trial reported in the Journal of Clinical Oncology, Fernando et al found that adjuvant brachytherapy did not improve risk for local recurrence after sublobar resection in patients with high-risk stage I operable...
A unique public-private collaboration among the National Cancer Institute (NCI), SWOG Cancer Research, Friends of Cancer Research, the Foundation for the National Institutes of Health (FNIH), five pharmaceutical companies (Amgen, Genentech, Pfizer, AstraZeneca, and AstraZeneca’s global...
In the first phase III trial assessing the combination of an insulin-like growth factor 1 receptor (IGF-1R) inhibitor with chemotherapy as first-line treatment for advanced nonadenocarcinoma non–small cell lung cancer (NSCLC), the addition of the fully human immunoglobulin G2 monoclonal...
In a study reported in the Journal of the National Cancer Institute, Tammemägi et al assessed smoking cessation rates among participants undergoing chest x-ray or computed tomography (CT) screening for lung cancer in the National Lung Screening Trial (NLST). Among patients without a subsequent ...
Around a quarter of smokers who carry a mutation in the BRCA2 gene will develop lung cancer at some point in their lifetime, a large-scale, international study reveals. Scientists described a previously unknown link between lung cancer and a particular BRCA2 mutation, which occurs in around 2% of...
In a phase I study, ceritinib (Zykadia) was found to shrink tumors in patients with anaplastic lymphoma kinase (ALK)-positive non–small cell lung cancer (NSCLC), regardless of whether patients had received previous treatment with an ALK inhibitor. The study was presented at the 2014 ASCO...